

## Special Issue

# Anticoagulants and Antiplatelet Drugs

### Message from the Guest Editor

Thrombosis-associated cardiovascular disorders are the leading cause of mortality worldwide. To counteract thrombosis, various anticoagulants and antiplatelet drugs have been successfully introduced into medical practice. New antithrombotic agents addressing alternative targets of the blood coagulation cascade and platelet surface receptors are still in the (pre)clinical developmental stage. This Special Issue aims to cover recent advances achieved in the field of anticoagulant and antiplatelet drug development. It covers previously unpublished experimental works in this field as well as theoretical papers assessing the current status of existing antithrombotic agents. Dr. Dmitrii V. Kalinin

### Guest Editor

Dr. Dmitrii Kalinin

Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany

### Deadline for manuscript submissions

closed (21 March 2023)



## Pharmaceuticals

an Open Access Journal  
by MDPI

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/si/109417](https://mdpi.com/si/109417)

*Pharmaceuticals*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)